---
title: "CanSinoBIO and JENKEM Strategic Cooperation to Explore New mRNA Vaccine Tumor Immunity Solutions"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/235229119.md"
description: "Recently, CanSinoBIO's subsidiary CanSino Biologics Co., Ltd. signed a cooperation development agreement with JENKEM's wholly-owned subsidiary Tianjin JENKEM Technology Co., Ltd. Both parties will jointly promote the clinical research project of mRNA vaccines for the treatment of glioblastoma, with the first patient administration expected to be completed within this year"
datetime: "2025-04-09T12:21:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/235229119.md)
  - [en](https://longbridge.com/en/news/235229119.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/235229119.md)
generator: "portal-rs"
---

# CanSinoBIO and JENKEM Strategic Cooperation to Explore New mRNA Vaccine Tumor Immunity Solutions

Recently, CanSinoBIO's subsidiary CanSinoBIO Co., Ltd. signed a cooperation development agreement with JENKEM's wholly-owned subsidiary Tianjin JENKEM Technology Co., Ltd. Both parties will jointly promote the clinical research project of mRNA vaccines for the treatment of glioblastoma, with the first patient administration expected to be completed within this year

### Related Stocks

- [688185.CN](https://longbridge.com/en/quote/688185.CN.md)
- [06185.HK](https://longbridge.com/en/quote/06185.HK.md)
- [688356.CN](https://longbridge.com/en/quote/688356.CN.md)

## Related News & Research

- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)
- [CanSino Biologics says China NMPA approves adsorbed tetanus vaccine NDA](https://longbridge.com/en/news/296476562.md)
- [CanSinoBIO spotlights meningococcal vaccine strategy at Asian pediatric infectious diseases congress](https://longbridge.com/en/news/296233860.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**